| scholarly article | Q13442814 |
| P2093 | author name string | Patrick Vandeputte | |
| Alix T Coste | |||
| Selene Ferrari | |||
| P2860 | cites work | New insights into the pleiotropic drug resistance network from genome-wide characterization of the YRR1 transcription factor regulation system. | Q24537249 |
| Overview of medically important antifungal azole derivatives | Q24617248 | ||
| Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors | Q24670154 | ||
| Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin | Q24674839 | ||
| Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. | Q25257687 | ||
| Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence | Q27318203 | ||
| Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution | Q27640699 | ||
| The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. | Q27931985 | ||
| A general strategy to uncover transcription factor properties identifies a new regulator of drug resistance in yeast. | Q27933644 | ||
| Yeast putative transcription factors involved in salt tolerance. | Q27935479 | ||
| Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase | Q27936187 | ||
| Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs | Q35124469 | ||
| Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia | Q35131728 | ||
| Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro | Q35132244 | ||
| Itraconazole resistance in Aspergillus fumigatus | Q35136791 | ||
| Molecular biological characterization of an azole-resistant Candida glabrata isolate | Q35138586 | ||
| New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species | Q35139501 | ||
| Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents | Q35165864 | ||
| Molecular mechanisms of itraconazole resistance in Candida dubliniensis | Q35165969 | ||
| A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. | Q35179541 | ||
| Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site | Q35216756 | ||
| Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors | Q35363744 | ||
| Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies | Q35644687 | ||
| Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora | Q35648327 | ||
| Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models. | Q35667405 | ||
| In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature | Q35904845 | ||
| Candida biofilm resistance | Q35943395 | ||
| Amphotericin B. | Q36094404 | ||
| Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates | Q36095337 | ||
| Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control | Q36114466 | ||
| An update on antifungal targets and mechanisms of resistance in Candida albicans | Q36235037 | ||
| Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin | Q36235197 | ||
| Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. | Q36314156 | ||
| Fungal biofilms and antimycotics | Q36352159 | ||
| Bone marrow toxicity associated with 5-fluorocytosine therapy | Q36459546 | ||
| Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity | Q36476427 | ||
| Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. | Q36563876 | ||
| Antifungal agents: mode of action in yeast cells | Q36590496 | ||
| Microreview of Pityriasis versicolor and Malassezia species | Q36674014 | ||
| The echinocandins | Q36742397 | ||
| A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. | Q36746995 | ||
| Resistance to echinocandin-class antifungal drugs | Q36849595 | ||
| ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. | Q36949532 | ||
| Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains | Q36993519 | ||
| Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact | Q37048679 | ||
| Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases | Q42246755 | ||
| Correlation between in vitro and in vivo activity of antifungal agents against Candida species | Q42283580 | ||
| Mutational Analysis of Flucytosine Resistance in Candida glabrata | Q42376066 | ||
| Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 | Q42408700 | ||
| Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes | Q42477429 | ||
| The central role of PDR1 in the foundation of yeast drug resistance | Q42505338 | ||
| Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance | Q42545813 | ||
| Calcineurin is required for virulence of Cryptococcus neoformans | Q42617596 | ||
| Molecular properties of amphotericin B membrane channel: a molecular dynamics simulation. | Q42668109 | ||
| A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance | Q42673167 | ||
| Large-scale gene disruption using the UAU1 cassette | Q42691326 | ||
| Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression | Q42708818 | ||
| A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus | Q42740228 | ||
| SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors | Q42742955 | ||
| Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences | Q42747700 | ||
| cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p | Q42909489 | ||
| Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth | Q42948674 | ||
| EUCAST breakpoints for antifungals | Q43108991 | ||
| Effects of voriconazole and vascular lesions in invasion of aspergillosis into the central nerve system | Q43261714 | ||
| Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei | Q43554693 | ||
| Functional isolation of the Candida albicans FCR3 gene encoding a bZip transcription factor homologous to Saccharomyces cerevisiae Yap3p | Q43740567 | ||
| Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol | Q43846832 | ||
| Homozygosity at the Candida albicans MTL locus associated with azole resistance | Q43946987 | ||
| Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate | Q44075306 | ||
| The effects of amphotericin B on pure and ergosterol- or cholesterol-containing dipalmitoylphosphatidylcholine bilayers as viewed by 2H NMR. | Q44149216 | ||
| The safety of voriconazole | Q44200945 | ||
| Function of Candida glabrata ABC transporter gene, PDH1. | Q44296093 | ||
| Antifungal agents. Part I. Amphotericin B preparations and flucytosine | Q44432591 | ||
| Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence | Q44444970 | ||
| Molecular characterization of ABC transporter-encoding genes in Aspergillus nidulans | Q44764644 | ||
| SRE1 and SRE2 are two specific steroid-responsive modules of Candida drug resistance gene 1 (CDR1) promoter | Q44767376 | ||
| Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida | Q44814572 | ||
| Antifungal agents. Part II. The azoles | Q45055511 | ||
| Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma | Q45162537 | ||
| Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents. | Q45918034 | ||
| Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). | Q46306343 | ||
| Studies of the paradoxical effect of caspofungin at high drug concentrations | Q46377599 | ||
| A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment | Q46495972 | ||
| An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. | Q46684704 | ||
| The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata | Q46724334 | ||
| Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans | Q47917035 | ||
| Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans | Q47940968 | ||
| Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans | Q37066510 | ||
| Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. | Q37072109 | ||
| Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance | Q37144914 | ||
| Efflux-mediated antifungal drug resistance. | Q37156645 | ||
| Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi | Q37160485 | ||
| Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains | Q37183937 | ||
| The Growing Problem of Mycoses in Patients Infected with the Human Immunodeficiency Virus | Q37229862 | ||
| Identification of the Candida albicans Cap1p regulon. | Q37232388 | ||
| Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals | Q37274696 | ||
| Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. | Q37301928 | ||
| Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. | Q37301949 | ||
| Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model | Q37410095 | ||
| The use of chitosan to damage Cryptococcus neoformans biofilms | Q37438897 | ||
| Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor | Q37568906 | ||
| CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1 | Q37625361 | ||
| Natural products--antifungal agents derived from plants | Q37698380 | ||
| Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. | Q37708398 | ||
| Echinocandin pharmacodynamics: review and clinical implications. | Q37718385 | ||
| Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis | Q37734345 | ||
| Epidemiology of invasive candidiasis | Q37780088 | ||
| Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneo | Q37786425 | ||
| Toenail onychomycosis: an important global disease burden | Q37787316 | ||
| Pharmacokinetics and tissue penetration of fluconazole in humans | Q37918375 | ||
| Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. | Q37919464 | ||
| Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance | Q38292045 | ||
| Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans | Q38302324 | ||
| Transcriptional control of the yeast PDR5 gene by the PDR3 gene product | Q38306711 | ||
| Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. | Q38311999 | ||
| Identification of a negative regulatory element which regulates basal transcription of a multidrug resistance gene CDR1 of Candida albicans. | Q38345779 | ||
| The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance | Q38363634 | ||
| Clinical use of systemic antifungal agents | Q39513650 | ||
| Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. | Q39558155 | ||
| Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants | Q39558473 | ||
| Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. | Q39559578 | ||
| Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi | Q77335306 | ||
| CHEMOTHERAPEUTIC ACTIVITY OF 5-FLUOROCYTOSINE | Q78290179 | ||
| The yeast zinc finger regulators Pdr1p and Pdr3p control pleiotropic drug resistance (PDR) as homo- and heterodimers in vivo | Q78577668 | ||
| The DNA-binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans | Q79149635 | ||
| Synthesis of 5-fluoropyrimidine metabolites | Q79221204 | ||
| Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction | Q79486437 | ||
| Large-scale gene function analysis in Candida albicans | Q79839447 | ||
| Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication? | Q79899830 | ||
| SOME NEW ASPECTS OF THE RELATIONSHIP OF CHEMICAL STRUCTURE TO BIOLOGICAL ACTIVITY | Q81008566 | ||
| Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY | Q82828933 | ||
| Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata | Q83100603 | ||
| The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors | Q83400317 | ||
| Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata | Q84551050 | ||
| A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. | Q51187404 | ||
| Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. | Q53583658 | ||
| Expression of the CDR1 efflux pump in clinical Candida albicans isolates is controlled by a negative regulatory element. | Q53856789 | ||
| Ketoconazole Blocks Adrenal Steroid Synthesis | Q53911940 | ||
| Analysis of the oxidative stress regulation of the Candida albicans transcription factor, Cap1p. | Q54049038 | ||
| CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole. | Q54072784 | ||
| Flucytosine monotherapy for cryptococcosis. | Q54127839 | ||
| Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. | Q54167579 | ||
| Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. | Q54383002 | ||
| Drug resistance in Candida albicans and Candida glabrata. | Q54394043 | ||
| Failure of Ketoconazole in Cryptococcal Meningitis | Q54516036 | ||
| Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance | Q54631149 | ||
| Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? | Q61546279 | ||
| Amphotericin B-resistant yeast infection in severely immunocompromised patients | Q68136440 | ||
| Toxicity of clotrimazole | Q68915228 | ||
| Evidence for a Common Transport System for Cytosine, Adenine and Hypoxanthine in Saccharomyces cerevisiae and Candida albicans | Q69237167 | ||
| Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system | Q69814579 | ||
| Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q69872789 | ||
| Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis Model | Q70257684 | ||
| Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry | Q70788217 | ||
| Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent | Q72145097 | ||
| Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation | Q72989562 | ||
| Multiple Yap1p-binding sites mediate induction of the yeast major facilitator FLR1 gene in response to drugs, oxidants, and alkylating agents | Q27937890 | ||
| War1p, a novel transcription factor controlling weak acid stress response in yeast. | Q27937997 | ||
| Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions | Q28143025 | ||
| Echinocandins: a new class of antifungal | Q28201851 | ||
| Antifungal resistance in pathogenic fungi | Q28208165 | ||
| Preventing parasites in cats | Q28282772 | ||
| Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent | Q28328110 | ||
| Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans | Q28344597 | ||
| Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors | Q28344744 | ||
| Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR | Q28361576 | ||
| MDR1-mediated drug resistance in Candida dubliniensis | Q28364120 | ||
| Mechanisms of action of 5-fluorocytosine | Q28366384 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. | Q28369044 | ||
| Essential gene identification and drug target prioritization in Aspergillus fumigatus | Q28469156 | ||
| Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans | Q28469241 | ||
| The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans | Q28469346 | ||
| Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence | Q28472787 | ||
| Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection | Q28475711 | ||
| Forward genetics in Candida albicans that reveals the Arp2/3 complex is required for hyphal formation, but not endocytosis. | Q30583463 | ||
| The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans | Q31536985 | ||
| Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p | Q33217380 | ||
| Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance | Q33258644 | ||
| Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae | Q33331281 | ||
| Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy | Q33357288 | ||
| Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells | Q33361111 | ||
| Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis | Q33449819 | ||
| A phenotypic profile of the Candida albicans regulatory network | Q33521302 | ||
| An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans | Q33559158 | ||
| TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. | Q33559776 | ||
| Natural products as antifungal agents against clinically relevant pathogens | Q33582329 | ||
| Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans | Q33593689 | ||
| Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity | Q33602928 | ||
| Lipopeptide inhibitors of fungal glucan synthase | Q34425782 | ||
| Mucormycoses | Q34443147 | ||
| Antifungal susceptibility testing. New technology and clinical applications | Q34486480 | ||
| Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants | Q34510712 | ||
| Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 | Q34529179 | ||
| Fungal biofilms and drug resistance | Q34540389 | ||
| Chromosome loss followed by duplication is the major mechanism of spontaneous mating-type locus homozygosis in Candida albicans | Q34572390 | ||
| Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase | Q34576400 | ||
| A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans | Q34588684 | ||
| Caspofungin: an echinocandin antifungal agent | Q34599632 | ||
| The influence of gastric acidity on the bio-availability of ketoconazole | Q34708079 | ||
| Disposition of ketoconazole, an oral antifungal, in humans | Q34708257 | ||
| Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus | Q34718619 | ||
| Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain | Q34721001 | ||
| Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase | Q34823914 | ||
| Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans | Q34932227 | ||
| Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. | Q34932972 | ||
| Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. | Q34940421 | ||
| Clinical relevance of mechanisms of antifungal drug resistance in yeasts | Q34993877 | ||
| Polyene macrolide antibiotics and their applications in human therapy | Q35060978 | ||
| Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate | Q33630438 | ||
| Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae | Q33634941 | ||
| Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans | Q33651856 | ||
| Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents | Q33689421 | ||
| Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis | Q33694469 | ||
| Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. | Q33699122 | ||
| Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. | Q33721804 | ||
| Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance | Q33749111 | ||
| Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene | Q33752151 | ||
| Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection | Q33768787 | ||
| Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. | Q33830384 | ||
| Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata | Q33847058 | ||
| Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans | Q33859372 | ||
| Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins | Q33883762 | ||
| New drugs and novel targets for treatment of invasive fungal infections in patients with cancer | Q33905634 | ||
| Voriconazole: a new triazole antifungal | Q33917339 | ||
| Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates | Q33938068 | ||
| Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes | Q33953578 | ||
| In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents | Q33959506 | ||
| The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. | Q33978099 | ||
| Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin | Q33978506 | ||
| Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy | Q33981794 | ||
| Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. | Q33981896 | ||
| Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients | Q33983022 | ||
| The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans | Q33991085 | ||
| Antifungal drug discovery through the study of invertebrate model hosts | Q34002069 | ||
| In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization | Q34071444 | ||
| Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis | Q34108536 | ||
| Amphotericin B: spectrum and resistance | Q34110285 | ||
| Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery | Q34264835 | ||
| Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans | Q34290134 | ||
| History of the development of azole derivatives | Q34293222 | ||
| Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators. | Q34411110 | ||
| Mechanisms of azole resistance in a clinical isolate of Candida tropicalis | Q39610249 | ||
| Quantitative analysis of the relative transcript levels of ABC transporter Atr genes in Aspergillus nidulans by real-time reverse transcription-PCR assay | Q39639247 | ||
| A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus | Q39731994 | ||
| Calcineurin is essential for Candida albicans survival in serum and virulence | Q39774463 | ||
| In vitro studies with R 51,211 (itraconazole) | Q39848866 | ||
| Positive autoregulation of the yeast transcription factor Pdr3p, which is involved in control of drug resistance | Q40016777 | ||
| Do Aspergillus species produce biofilm? | Q40129725 | ||
| Clinical pharmacokinetics of systemic antifungal drugs | Q40134408 | ||
| Strategies in the treatment of systemic fungal infections | Q40280261 | ||
| Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections | Q40282229 | ||
| Molecular mechanisms of primary resistance to flucytosine in Candida albicans | Q40289630 | ||
| Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. | Q40295704 | ||
| The fungal cell wall as a drug target | Q40540808 | ||
| Molecular mechanisms of drug resistance in fungi | Q40589073 | ||
| Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism | Q40737822 | ||
| Compounds active against cell walls of medically important fungi | Q40889532 | ||
| In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata | Q41028056 | ||
| Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles | Q41370116 | ||
| Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate | Q41473540 | ||
| A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 | ||
| Systemic antifungal agents. Drug interactions of clinical significance | Q41725883 | ||
| A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata | Q41774705 | ||
| Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints | Q41787736 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae | Q41816687 | ||
| Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain | Q41846354 | ||
| Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility | Q41957394 | ||
| A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. | Q42048818 | ||
| Effect of thiolated polymers to textural and mucoadhesive properties of vaginal gel formulations prepared with polycarbophil and chitosan | Q42109106 | ||
| Aneuploidy and isochromosome formation in drug-resistant Candida albicans | Q42113364 | ||
| Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin | Q42119802 | ||
| Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) | Q42169461 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 713687 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | International Journal of Microbiology | Q26841927 |
| P1476 | title | Antifungal resistance and new strategies to control fungal infections | |
| P478 | volume | 2012 |
| Q33766309 | A Chitin-binding Protein Purified from Moringa oleifera Seeds Presents Anticandidal Activity by Increasing Cell Membrane Permeability and Reactive Oxygen Species Production |
| Q40869719 | Acidophilic actinobacteria synthesised silver nanoparticles showed remarkable activity against fungi-causing superficial mycoses in humans |
| Q58090050 | Alexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens |
| Q48095380 | Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents |
| Q64240636 | Amides Derived from Vanillic Acid: Coupling Reactions, Antimicrobial Evaluation, and Molecular Docking |
| Q35448907 | An assessment of growth media enrichment on lipid metabolome and the concurrent phenotypic properties of Candida albicans |
| Q40796297 | An overview about the medical use of antifungals in Portugal in the last years |
| Q39228094 | Anti-Rhodotorula activity of mycophenolic acid enhanced in the presence of polyene antibiotic nystatin |
| Q46270242 | Antibacterial and antifungal activity activity of pyroligneous acid from wood of Eucalyptus urograndis and Mimosa tenuiflora |
| Q58776220 | Antifungal Resistance in Dermatology |
| Q61808721 | Antifungal Susceptibility of Dermatophytes Isolated From Cutaneous Fungal Infections: The Vietnamese Experience |
| Q39273596 | Antifungal activity of dual combination of hydroxychavicol with commercialized agents against oral Candida species |
| Q37381931 | Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development |
| Q64286131 | Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications |
| Q92603783 | Antifungal effects of indolicidin-conjugated gold nanoparticles against fluconazole-resistant strains of Candida albicans isolated from patients with burn infection |
| Q50122600 | Antifungals discovery: an insight into new strategies to combat antifungal resistance |
| Q38684281 | Antifungals: Mechanism of Action and Drug Resistance |
| Q90015860 | Antimicrobial activities of Tephrosia vogelii against selected pathogenic fungi and bacteria strains |
| Q35933700 | Antimicrobial blue light inactivation of Candida albicans: In vitro and in vivo studies |
| Q40459122 | Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice. |
| Q35607733 | Azole drug import into the pathogenic fungus Aspergillus fumigatus. |
| Q26863344 | Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents |
| Q26770698 | Clinical Appearance of Oral Candida Infection and Therapeutic Strategies |
| Q38314467 | Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients |
| Q35881281 | Clinical significance of the isolation of Candida species from hospitalized patients |
| Q28552912 | Comparison of Chemical Sensitivity of Fresh and Long-Stored Heat Resistant Neosartorya fischeri Environmental Isolates Using BIOLOG Phenotype MicroArray System |
| Q40090449 | Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs. |
| Q30558805 | Computational approaches for discovery of common immunomodulators in fungal infections: towards broad-spectrum immunotherapeutic interventions |
| Q41382937 | Control of human and plant fungal pathogens using pentaene macrolide 32, 33-didehydroroflamycoin |
| Q37359653 | Deletion of the HAMP domains from the histidine kinase CaNik1p of Candida albicans or treatment with fungicides activates the MAP kinase Hog1p in S. cerevisiae transformants |
| Q46393306 | Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients |
| Q33692141 | Diversity, in-vitro virulence traits and antifungal susceptibility pattern of gastrointestinal yeast flora of healthy poultry, Gallus gallus domesticus |
| Q30248243 | Drug resistance in eukaryotic microorganisms |
| Q36155799 | Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells |
| Q26748172 | Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species |
| Q58575295 | Effect of seasonality on chemical profile and antifungal activity of essential oil isolated from leaves (Kunth) O. Berg |
| Q39048482 | Emerging biopharmaceuticals from bioactive peptides derived from marine organisms |
| Q41355547 | Endophytic fungal compounds active against Cryptococcus neoformans and C. gattii |
| Q37428629 | Endosomal Trafficking Defects Can Induce Calcium-Dependent Azole Tolerance in Candida albicans |
| Q37417354 | Epidemiology and changes in patient-related factors from 1997 to 2009 in clinical yeast isolates related to dermatology, gynaecology, and paediatrics |
| Q47646968 | Fluconazole Resistance among Oral Candida Isolates from People Living with HIV/AIDS in a Nigerian Tertiary Hospital |
| Q27687259 | From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials |
| Q36308715 | Functional characterization of cytochrome P450 monooxygenases in the cereal head blight fungus Fusarium graminearum. |
| Q38192062 | Fungus-associated asthma: overcoming challenges in diagnosis and treatment. |
| Q94525600 | Green Synthesis, Characterization and Antimicrobial Activity of Copper Oxide Nanomaterial Derived from Momordica charantia |
| Q47412545 | Heterologous expression of mitochondrial nicotinamide adenine dinucleotide transporter (Ndt1) from Aspergillus fumigatus rescues impaired growth in Δndt1Δndt2 Saccharomyces cerevisiae strain |
| Q39404146 | Heteroresistance and fungi. |
| Q34729487 | High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors |
| Q53779321 | Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug. |
| Q37247203 | Identification of Candida species and susceptibility testing with Sensititre YeastOne microdilution panel to 9 antifungal agents |
| Q92606226 | Identification of novel antifungal agents: antimicrobial evaluation, SAR, ADME-Tox and molecular docking studies of a series of imidazole derivatives |
| Q52756196 | In Vitro Antifungal Activity of Hexahydropyrimidine Derivatives against the Causative Agents of Dermatomycosis. |
| Q38989873 | In vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens. |
| Q64242716 | Investigating Antifungal Susceptibility in Species With MALDI-TOF MS-Based Assays |
| Q38932794 | Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review |
| Q35842813 | Isolation and characterization of an antifungal compound 5-hydroxy-7,4'-dimethoxyflavone from Combretum zeyheri. |
| Q89864916 | Lactoferrin is broadly active against yeasts and highly synergistic with amphotericin B |
| Q38836667 | MFS transporters of Candida species and their role in clinical drug resistance. |
| Q34942381 | ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans |
| Q89494813 | Machine Learning Approach for Candida albicans Fluconazole Resistance Detection Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry |
| Q89633203 | Methylcellulose Hydrogel with Melissa officinalis Essential Oil as a Potential Treatment for Oral Candidiasis |
| Q38206867 | Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? |
| Q49679775 | Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines |
| Q57900034 | Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products |
| Q48163141 | Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds. |
| Q41677089 | Neutron diffraction studies of the interaction between amphotericin B and lipid-sterol model membranes |
| Q46244030 | New Application of Neomycin B-Bisbenzimidazole Hybrids as Antifungal Agents. |
| Q34980533 | New insights concerning the occurrence of fungi in water sources and their potential pathogenicity. |
| Q38743672 | Newer patents in antimycotic therapy |
| Q57818139 | Novel Combinations of Agents Targeting Translation That Synergistically Inhibit Fungal Pathogens |
| Q33636471 | Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation |
| Q55371002 | Oropharyngeal Candidosis in HIV-Infected Patients-An Update. |
| Q91739554 | Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities |
| Q36324972 | Photodynamic inactivation of Paracoccidioides brasiliensis helps the outcome of oral paracoccidiodomycosis |
| Q26743448 | Potential Roles of Fungal Extracellular Vesicles during Infection |
| Q39315981 | Potential of novel drug delivery systems in the management of topical candidiasis |
| Q40602135 | Prevalence and Fluconazole Susceptibility Profile of Candida spp. Clinical Isolates in a Brazilian Tertiary Hospital in Minas Gerais, Brazil |
| Q44498812 | Rational Design of Glycomimetic Compounds Targeting the Saccharomyces cerevisiae Transglycosylase Gas2. |
| Q36266986 | Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway |
| Q35657134 | Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans |
| Q34276700 | Resistance to antifungals that target CYP51. |
| Q92071802 | Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris |
| Q64231096 | Screening and Antifungal Activity of a -Carboline Derivative against and |
| Q35108316 | Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro |
| Q38794452 | Sodium ascorbate kills Candida albicans in vitro via iron-catalyzed Fenton reaction: importance of oxygenation and metabolism |
| Q38833311 | Sphingolipids as targets for treatment of fungal infections |
| Q59808687 | Synergistic Effect of Quinic Acid Derived From and Undecanoic Acid Against spp. Biofilm and Virulence |
| Q61450746 | Synthesis and Spectroscopic Identification of Certain Imidazole-Semicarbazone Conjugates Bearing Benzodioxole Moieties: New Antifungal Agents |
| Q47748935 | Synthesis, characterization and evaluation of antimicrobial and cytotoxic activities of biogenic silver nanoparticles synthesized from Streptomyces xinghaiensis OF1 strain |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
| Q40737202 | Targeted Disruption of Melanin Biosynthesis Genes in the Human Pathogenic Fungus Lomentospora prolificans and Its Consequences for Pathogen Survival |
| Q38917135 | Targeting CYP51 for drug design by the contributions of molecular modeling. |
| Q91726605 | The Evolution of Azole Resistance in Candida albicans Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid Substitutions |
| Q37562147 | The Mechanistic Targets of Antifungal Agents: An Overview |
| Q38009721 | The effect of biomaterials and antifungals on biofilm formation by Candida species: a review |
| Q38835045 | The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies |
| Q47934743 | Theoretical Reactivity Study of Indol-4-Ones and Their Correlation with Antifungal Activity |
| Q58762553 | Therapy and Antifungal Susceptibility Profile of |
| Q35168990 | Trafficking through the late endosome significantly impacts Candida albicans tolerance of the azole antifungals |
| Q90400975 | Two New 1,3,4-Oxadiazoles With Effective Antifungal Activity Against Candida albicans |
| Q28543581 | Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
Search more.